Immunological correlates of treatment and response in stage IV malignant melanoma patients treated with Ipilimumab - Wikidata - wikimedia - TriplyDB

Immunological correlates of treatment and response in stage IV malignant melanoma patients treated with Ipilimumab

Immunological correlates of treatment and response in stage IV malignant melanoma patients treated with Ipilimumab

http://www.wikidata.org/entity/Q36821143

about

Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting Targeting Immune Regulatory Networks to Counteract Immune Suppression in Cancer Immune biomarkers for chronic inflammation related complications in non-cancerous and cancerous diseases.Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers.Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells.Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review.Clinical implication of tumor-associated and immunological parameters in melanoma patients treated with ipilimumab.Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma.Baseline laboratory parameters predicting clinical outcome in melanoma patients treated with ipilimumab: a single-centre analysis.Systemic inflammation is associated with the density of immune cells in the tumor microenvironment of gastric cancer.Development of anti-drug antibodies is associated with shortened survival in patients with metastatic melanoma treated with ipilimumab.Turn Back the TIMe: Targeting Tumor Infiltrating Myeloid Cells to Revert Cancer Progression

P2860

Q26742012-8BDBCCBA-1BFB-4C7E-A05B-2BD6D2B8A18B Q28066486-66F4DB2F-8B78-43FA-9FDC-92CD1E95E6F0 Q39412983-BF960D10-E55C-45DC-A11E-281803759753 Q41899044-1B1FB5F5-8D1D-44FA-94E1-1A499C14DF32 Q41974388-28B2A3DD-B98B-47B4-A8B6-AECB7E3CA9C9 Q42369277-944B0E12-E0D9-4763-A483-2BFF4471C475 Q42968783-6C55630F-9D0D-47F8-A762-E7800F1CB9B9 Q47157659-4844DC29-23BA-4174-8AB6-83ADA7012E79 Q47812209-2D66AB67-8DD5-4C67-B205-7D3E45F0CA25 Q48336799-09FCA141-EAF6-4EE6-81A7-7FDEBB7FD3D6 Q55342245-88200E23-3C6A-49B5-9692-EFE9F8C6E545 Q58780996-CB46C5EA-C03A-4DEE-B07A-A0068200D171

P2860

Immunological correlates of treatment and response in stage IV malignant melanoma patients treated with Ipilimumab

http://www.wikidata.org/entity/Q36821143

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Immunological correlates of tr ...... tients treated with Ipilimumab

@en

type

label

Immunological correlates of tr ...... tients treated with Ipilimumab

@en

prefLabel

Immunological correlates of tr ...... tients treated with Ipilimumab

@en

P1433

Q36821143-44FAD4C3-50B4-4C09-ADE6-46EF4CDFD9B1

P1476

Q36821143-FAAB627C-A3D8-4007-9E6D-851B49651996

P2093

Q36821143-47C689CD-7CB5-444F-AB72-6C1E3A223D8F

Q36821143-80D5C9CC-0E0C-418F-B1DC-DCF6DBA2691F

Q36821143-880BFC4B-8DC0-41DB-8CC1-200AF97C9909

Q36821143-958CE200-A857-43A4-A364-38151B721DBA

Q36821143-9BFA8217-9524-47E5-994A-15AFB79C0738

P2860

Q36821143-033E13DD-B362-4240-8F22-76BA6D65A3F4

Q36821143-0B62E702-AFB1-411B-A383-1059452B7A30

Q36821143-0B752B1B-C7D6-464B-ABF9-794C1F4825EE

Q36821143-10CACC32-68AE-4521-86F4-3D2396D33B75

Q36821143-1322D5ED-AA46-4379-8781-07CC4AB02764

Q36821143-1607458F-627C-4D2D-A008-4B758DDBE564

Q36821143-193E8D45-303E-4197-825D-DB2F00E6CD58

Q36821143-1FA1E845-A204-4EBA-91CC-D0891618B14A

Q36821143-2499EC5C-4F6E-4A0B-897A-6F002848EF0C

Q36821143-28311F85-B084-4C74-9F2F-0F15E022A528

P304

Q36821143-63B66FE6-87A5-47D2-9E5F-401CCCB8C783

P31

Q36821143-1193A2A5-01A8-4790-BC9B-42639B372DC2

P356

Q36821143-0F13818E-B00A-4032-A2D6-C6D191D4278E

P433

Q36821143-79B78ACF-F018-4BD7-B441-8707AC3E8439

P478

Q36821143-5856F3CB-19B5-4C9E-94A2-3838AB086ADB

P50

Q36821143-9C1E832D-1ECE-469D-818B-EED48839599B

P577

Q36821143-34F6D541-4F93-42F2-A03E-F0977C13737E

P698

Q36821143-575B18E6-EA08-4482-8FE6-E1638DAA324D

P921

Q36821143-33557157-AE63-4ADE-9BAD-56E8E5FE2CCD

Q36821143-9FB75ED9-E22C-49E8-8A67-6848A2C9BC34

P932

Q36821143-C080899E-E07A-4C42-B316-24A8F510C2EC

P356

2162402X.2015.1100788

P1433

P1476

Immunological correlates of tr ...... tients treated with Ipilimumab

@en

P2093

Henrik Schmidt

http://www.w3.org/2001/XMLSchema#string

Jon Bjoern

http://www.w3.org/2001/XMLSchema#string

Kirsten Fode

http://www.w3.org/2001/XMLSchema#string

Nikolaj Juul Nitschke

http://www.w3.org/2001/XMLSchema#string

Trine Zeeberg Iversen

http://www.w3.org/2001/XMLSchema#string

P2860

Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma

BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination

CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

LAP, a lymphocyte activation gene-3 (LAG-3)-associated protein that binds to a repeated EP motif in the intracellular region of LAG-3, may participate in the down-regulation of the CD3/TCR activation pathway

CTLA-4 can function as a negative regulator of T cell activation

Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression.

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Genetic basis for clinical response to CTLA-4 blockade in melanoma

CTLA4 blockade broadens the peripheral T-cell receptor repertoire

P304

e1100788

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/2162402X.2015.1100788

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

Inge Marie Svane

P577

2015-11-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27141381

http://www.w3.org/2001/XMLSchema#string

P921

P932

4839337

http://www.w3.org/2001/XMLSchema#string